Plain-English translation of NCT06484335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether two special antibodies called and , given together with a series of HIV vaccines, can help your immune system learn to control HIV on its own. The goal is to see if people with HIV who started treatment very early in their infection might eventually need less or no daily medication to keep the virus suppressed.
Most people with HIV need to take daily medication for life to keep the virus under control. This trial is exploring whether this new treatment might help train your immune system to do that job itself, which could mean fewer pills and more freedom for people living with HIV.
You likely qualify if…
You likely don't qualify if…
If you join, you would receive two infusions of the special antibodies, followed by several vaccine injections over a few months. You would continue taking your regular HIV medication during most of the study, with regular blood tests to monitor your health and how your immune system responds. The study involves multiple clinic visits over several months to receive the treatments and have blood work done to track your progress.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
Thailand